Nicola Klein to Respiratory Syncytial Virus Infections
This is a "connection" page, showing publications Nicola Klein has written about Respiratory Syncytial Virus Infections.
Connection Strength
2.417
-
Maternal Vaccination vs Nirsevimab Use and Respiratory Syncytial Virus Infection Among Full-Term Infants. JAMA Netw Open. 2026 Oct 01; 9(10):e2636760.
Score: 0.939
-
Effectiveness of Nirsevimab Against RSV and RSV-Related Events in Infants. Pediatrics. 2025 Aug 01; 156(2).
Score: 0.866
-
Near real-time surveillance and tree-based data mining to assess the safety of respiratory syncytial virus vaccines in older adults in the vaccine safety datalink. Vaccine. 2025 Nov 20; 67:127873.
Score: 0.220
-
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. Lancet. 2024 Oct 19; 404(10462):1547-1559.
Score: 0.205
-
Evaluation of Clinical Case Definitions for Respiratory Syncytial Virus Lower Respiratory Tract Infection in Young Children. J Pediatric Infect Dis Soc. 2023 May 31; 12(5):273-281.
Score: 0.186